Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma 24Lymphoma, Non-Hodgkin 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Myeloid, Acute 9Leukemia 9Neuroblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Hodgkin Disease 8Central Nervous System Neoplasms 8Medulloblastoma 7Rhabdoid Tumor 6Recurrence 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, B-Cell, Marginal Zone 6Burkitt Lymphoma 6Neoplasms, Germ Cell and Embryonal 5Lymphoma, Follicular 5Lymphoma, B-Cell 5Glioma 5Brain Neoplasms 5Sarcoma 4Ovarian Neoplasms 4Oligodendroglioma 4Neoplasms 4Lung Neoplasms 4Immunoblastic Lymphadenopathy 4Astrocytoma 4

Interventions

eltrombopag 9avatrombopag 6Platelet Transfusion 6romiplostim 4Tranexamic Acid 3Radiotherapy 3Cytarabine 3oprelvekin 2hetrombopag 2Tretinoin 2Peripheral Blood Stem Cell Transplantation 2Filgrastim 2Cyclophosphamide 2Carboplatin 2Busulfan 2Amplified Fragment Length Polymorphism Analysis 2sodium thiosulfate 1siltuximab 1raltitrexed 1pegfilgrastim 1ofatumumab 1niraparib 1leridistim 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1apixaban 1Vorinostat 1Vitamin B 12 1Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thrombocytopenia × etoposide phosphate × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡